The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patients

1. Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev 2019, 36: 70–87. doi: 10.1016/j.blre.2019.04.005 ShallisRM WangR DavidoffA MaX ZeidanAM Epidemiology of acute myeloid leukemia: recent progress and enduring challenges Blood Rev 2019 36 70 87 10.1016/j.blre.2019.04.005 Open DOISearch in Google Scholar

2. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022, 140: 1345–77. doi: 10.1182/blood.2022016867 DöhnerH WeiAH AppelbaumFR CraddockC DiNardoCD DombretH Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN Blood 2022 140 1345 77 10.1182/blood.2022016867 Open DOISearch in Google Scholar

3. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016, 127: 2391–405. doi: 10.1182/blood-2016-03-643544 ArberDA OraziA HasserjianR ThieleJ BorowitzMJ Le BeauMM The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Blood 2016 127 2391 405 10.1182/blood-2016-03-643544 Open DOISearch in Google Scholar

4. Fleischmann M, Schnetzke U, Hochhaus A, Scholl S. Management of acute myeloid leukemia: current treatment options and future perspectives. Cancers, 2021, 13: 5722. doi: 10.3390/cancers13225722 FleischmannM SchnetzkeU HochhausA SchollS Management of acute myeloid leukemia: current treatment options and future perspectives Cancers 2021 13 5722 10.3390/cancers13225722 Open DOISearch in Google Scholar

5. Shaffer BC, Gillet JP, Patel C, Baer MR, Bates SE, Gottesman MM. Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat 2012, 15: 62–9. doi: 10.1016/j.drup.2012.02.001 ShafferBC GilletJP PatelC BaerMR BatesSE GottesmanMM Drug resistance: still a daunting challenge to the successful treatment of AML Drug Resist Updat 2012 15 62 9 10.1016/j.drup.2012.02.001 Open DOISearch in Google Scholar

6. Wang X, Wang C, Qin YW, Yan SK, Gao YR. Simultaneous suppression of multidrug resistance and antiapoptotic cellular defense induces apoptosis in chemoresistant human acute myeloid leukemia cells. Leuk Res 2007, 31: 989–94. doi: 10.1016/j.leukres.2006.09.001 WangX WangC QinYW YanSK GaoYR Simultaneous suppression of multidrug resistance and antiapoptotic cellular defense induces apoptosis in chemoresistant human acute myeloid leukemia cells Leuk Res 2007 31 989 94 10.1016/j.leukres.2006.09.001 Open DOISearch in Google Scholar

7. Svirnovski AI, Shman TV, Serhiyenka TF, Savitski VP, Smolnikova VV, Fedasenka UU. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. Hematology 2009, 14: 204–12. doi: 10.1179/102453309X426218 SvirnovskiAI ShmanTV SerhiyenkaTF SavitskiVP SmolnikovaVV FedasenkaUU ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells Hematology 2009 14 204 12 10.1179/102453309X426218 Open DOISearch in Google Scholar

8. Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer 2018; 18: 452–64. doi: 10.1038/s41568-018-0005-8 RobeyRW PluchinoKM HallMD FojoAT BatesSE GottesmanMM Revisiting the role of ABC transporters in multidrug-resistant cancer Nat Rev Cancer 2018 18 452 64 10.1038/s41568-018-0005-8 Open DOISearch in Google Scholar

9. Kulsoom B, Shamsi TS, Afsar NA, Memon Z, Ahmed N, Hasnain SN. Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy? Cancer Manag Res 2018, 10: 403–16. doi: 10.2147/CMAR.S154608 KulsoomB ShamsiTS AfsarNA MemonZ AhmedN HasnainSN Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy? Cancer Manag Res 2018 10 403 16 10.2147/CMAR.S154608 Open DOISearch in Google Scholar

10. Wu H, Medeiros LJ, Young KH. Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances. Blood Rev 2018, 32: 8–28. doi: 10.1016/j.blre.2017.08.004 WuH MedeirosLJ YoungKH Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances Blood Rev 2018 32 8 28 10.1016/j.blre.2017.08.004 Open DOISearch in Google Scholar

11. Handschuh L, Wojciechowski P, Kazmierczak M, Lewandowski K. Transcript-level dysregulation of BCL2 family genes in acute myeloblastic leukemia. Cancers 2021, 13: 3175. doi: 10.3390/cancers13133175 HandschuhL WojciechowskiP KazmierczakM LewandowskiK Transcript-level dysregulation of BCL2 family genes in acute myeloblastic leukemia Cancers 2021 13 3175 10.3390/cancers13133175 Open DOISearch in Google Scholar

12. Zhou JD, Zhang TJ, Xu ZJ, Gu Y, Ma JC, Li XX, et al. BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia. Diagn Pathol 2019, 14: 68. doi: 10.1186/s13000-019-0841-1. ZhouJD ZhangTJ XuZJ GuY MaJC LiXX BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia Diagn Pathol 2019 14 68 10.1186/s13000-019-0841-1 Open DOISearch in Google Scholar

13. Tiribelli M, Michelutti A, Cavallin M, Di Giusto S, Simeone E, Fanin R, et al. BCL-2 expression in AML patients over 65 years: impact on outcomes across different therapeutic strategies. J Clin Med 2021, 10: 5096. doi: 10.3390/jcm10215096 TiribelliM MicheluttiA CavallinM Di GiustoS SimeoneE FaninR BCL-2 expression in AML patients over 65 years: impact on outcomes across different therapeutic strategies J Clin Med 2021 10 5096 10.3390/jcm10215096 Open DOISearch in Google Scholar

14. Richard-Carpentier G, DiNardo CD. Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. Ther Adv Hematol 2019, 10: 2040620719882822. doi: 10.1177/2040620719882822 Richard-CarpentierG DiNardoCD Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy Ther Adv Hematol 2019 10 2040620719882822. 10.1177/2040620719882822 Open DOISearch in Google Scholar

15. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res 1999, 59: 1693s–700s. PMID: 10197582 KorsmeyerSJ BCL-2 gene family and the regulation of programmed cell death Cancer Res 1999 59 1693s 700s PMID: 10197582 Search in Google Scholar

16. Ong YL, McMullin MF, Bailie KE, Lappin TR, Jones FG, Irvine AE. High bax expression is a good prognostic indicator in acute myeloid leukaemia. Br J Haematol 2000, 111: 182–9. doi: 10.1046/j.1365-2141.2000.02315.x OngYL McMullinMF BailieKE LappinTR JonesFG IrvineAE High bax expression is a good prognostic indicator in acute myeloid leukaemia Br J Haematol 2000 111 182 9 10.1046/j.1365-2141.2000.02315.x Open DOISearch in Google Scholar

17. Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O’Brien S, Cortes J, et al. BAX and PKCa modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res 2000, 6: 1401–9. PMID: 10778970 KornblauSM VuHT RuvoloP EstrovZ O’BrienS CortesJ BAX and PKCa modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia Clin Cancer Res 2000 6 1401 9 PMID: 10778970 Search in Google Scholar

18. Kohler T, Schill C, Deininger MW, Krahl R, Borchert S, Hasenclever D, et al. High Bad and BAX mRNA expression correlate with negative outcome in acute myeloid leukemia (AML). Leukemia 2002, 16: 22–9. doi: 10.1038/sj.leu.2402340 KohlerT SchillC DeiningerMW KrahlR BorchertS HasencleverD High Bad and BAX mRNA expression correlate with negative outcome in acute myeloid leukemia (AML) Leukemia 2002 16 22 9 10.1038/sj.leu.2402340 Open DOISearch in Google Scholar

19. Del Poeta G, Venditti A, Del Principe MI, Maurillo L, Buccisano F, Tamburini A, et al. Amount of spontaneous apoptosis detected by BAX/BCL2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003, 101: 2125–31. doi: 10.1182/blood-2002-06-1714 Del PoetaG VendittiA Del PrincipeMI MaurilloL BuccisanoF TamburiniA Amount of spontaneous apoptosis detected by BAX/BCL2 ratio predicts outcome in acute myeloid leukemia (AML) Blood 2003 101 2125 31 10.1182/blood-2002-06-1714 Open DOISearch in Google Scholar

20. Vazanova A, Jurecekova J, Balharek T, Marcinek J, Stasko J, Dzian A, et al. Differential mRNA expression of the main apoptotic proteins in normal and malignant cells and its relation to in vitro resistance. Cancer Cell Int 2018, 18: 33. doi: 10.1186/s12935-018-0528-9. VazanovaA JurecekovaJ BalharekT MarcinekJ StaskoJ DzianA Differential mRNA expression of the main apoptotic proteins in normal and malignant cells and its relation to in vitro resistance Cancer Cell Int 2018 18 33 10.1186/s12935-018-0528-9 Open DOISearch in Google Scholar

21. Chen CJ, Clark D, Ueda K, Pastan I, Gottesman MM, Roninson IB. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 1990, 265: 506–14. PMID: 1967175 ChenCJ ClarkD UedaK PastanI GottesmanMM RoninsonIB Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins J Biol Chem 1990 265 506 14 PMID: 1967175 Search in Google Scholar

22. Gerlach JH, Endicott JA, Juranka PF, Henderson G, Sarangi F, Deuchars KL, et al. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 1986, 324: 485–9. doi: 10.1038/324485a0 GerlachJH EndicottJA JurankaPF HendersonG SarangiF DeucharsKL Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance Nature 1986 324 485 9 10.1038/324485a0 Open DOISearch in Google Scholar

23. Pallis M, Turzanski J, Higashi Y, Russell N. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma 2002, 43: 1221–8. doi: 10.1080/10428190290026277 PallisM TurzanskiJ HigashiY RussellN P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype Leuk Lymphoma 2002 43 1221 8 10.1080/10428190290026277 Open DOISearch in Google Scholar

24. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620–5. doi: 10.7326/0003-4819-103-4-620 BennettJM CatovskyD DanielMT FlandrinG GaltonDA GralnickHR Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group Ann Intern Med 1985 103 620 5 10.7326/0003-4819-103-4-620 Open DOISearch in Google Scholar

25. McGowan-Jordan J, Simons A, Schmid M. ISCN 2016 An International System for Human Cytogenomic Nomenclature. Basel: Karger; 2016. doi: 10.1159/isbn.978-3-318-06861-0 McGowan-JordanJ SimonsA SchmidM ISCN 2016 An International System for Human Cytogenomic Nomenclature Basel Karger 2016 10.1159/isbn.978-3-318-06861-0 Open DOISearch in Google Scholar

26. Béné MC, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W, et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia 2011; 25: 567–74. doi: 10.1038/leu.2010.312 BénéMC NebeT BettelheimP BuldiniB BumbeaH KernW Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10 Leukemia 2011 25 567 74 10.1038/leu.2010.312 Open DOISearch in Google Scholar

27. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642–9. doi: 10.1200/JCO.2003.04.036 ChesonBD BennettJM KopeckyKJ BüchnerT WillmanCL EsteyEH Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia J Clin Oncol 2003 21 4642 9 10.1200/JCO.2003.04.036 Open DOISearch in Google Scholar

28. Vucicevic K, Jakovljevic V, Colovic N, Tosic N, Kostic T, Glumac I, et al. Association of Bax expression and Bcl2/Bax ratio with clinical and molecular prognostic markers in chronic lymphocytic leukemia. J Med Biochem 2016, 35: 150–7. doi: 10.1515/jomb-2015-0017 VucicevicK JakovljevicV ColovicN TosicN KosticT GlumacI Association of Bax expression and Bcl2/Bax ratio with clinical and molecular prognostic markers in chronic lymphocytic leukemia J Med Biochem 2016 35 150 7 10.1515/jomb-2015-0017 Open DOISearch in Google Scholar

29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402–8. doi: 10.1006/meth.2001.1262 LivakKJ SchmittgenTD Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method Methods 2001 25 402 8 10.1006/meth.2001.1262 Open DOISearch in Google Scholar

30. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101–8. doi: 10.1038/nprot.2008.73 SchmittgenTD LivakKJ Analyzing real-time PCR data by the comparative C(T) method Nat Protoc 2008 3 1101 8 10.1038/nprot.2008.73 Open DOISearch in Google Scholar

31. Mitrovic M, Kostic T, Virijevic M, Karan-Djurasevic T, Suvajdzic Vukovic N, Pavlovic S, et al. The influence of Wilms’ tumor 1 gene expression level on prognosis and risk stratification of acute promyelocytic leukemia patients. Int J Lab Hematol 2020, 42: 82–7. doi: 10.1111/ijlh.13144 MitrovicM KosticT VirijevicM Karan-DjurasevicT Suvajdzic VukovicN PavlovicS The influence of Wilms’ tumor 1 gene expression level on prognosis and risk stratification of acute promyelocytic leukemia patients Int J Lab Hematol 2020 42 82 7 10.1111/ijlh.13144 Open DOISearch in Google Scholar

32. Kuzmanovic M, Tosic N, Colovic N, Karan-Djurasevic T, Spasovski V, Radmilovic M, et al. Prognostic impact of NPM1 mutations in Serbian adult patients with acute myeloid leukemia. Acta Haematol 2012, 128: 203–12. doi: 10.1159/000339506 KuzmanovicM TosicN ColovicN Karan-DjurasevicT SpasovskiV RadmilovicM Prognostic impact of NPM1 mutations in Serbian adult patients with acute myeloid leukemia Acta Haematol 2012 128 203 12 10.1159/000339506 Open DOISearch in Google Scholar

33. Dabrowska M, Pietruczuk M, Kostecka I, Suchowierska M, Kloczko J, Nasilowska B, et al. The rate of apoptosis and expression of Bcl-2 and Bax in leukocytes of acute myeloblastic leukemia patients. Neoplasma 2003, 50: 339–44. PMID: 14628086 DabrowskaM PietruczukM KosteckaI SuchowierskaM KloczkoJ NasilowskaB The rate of apoptosis and expression of Bcl-2 and Bax in leukocytes of acute myeloblastic leukemia patients Neoplasma 2003 50 339 44 PMID: 14628086 Search in Google Scholar

34. Tzifi F, Economopoulou C, Gourgiotis D, Ardavanis A, Papageorgiou S, Scorilas A. The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias. Adv Hematol 2012, 2012: 524308. doi: 10.1155/2012/524308 TzifiF EconomopoulouC GourgiotisD ArdavanisA PapageorgiouS ScorilasA The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias Adv Hematol 2012 2012 524308 10.1155/2012/524308 Open DOISearch in Google Scholar

35. Haes I, Dendooven A, Mercier ML, Puylaert P, Vermeulen K, Kockx M, et al. Absence of BCL-2 expression identifies a subgroup of AML with distinct phenotypic, molecular, and clinical characteristics. J Clin Med 2020, 9: 3090. doi: 10.3390/jcm9103090 HaesI DendoovenA MercierML PuylaertP VermeulenK KockxM Absence of BCL-2 expression identifies a subgroup of AML with distinct phenotypic, molecular, and clinical characteristics J Clin Med 2020 9 3090 10.3390/jcm9103090 Open DOISearch in Google Scholar

36. Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 1999, 13: 1881–92. doi: 10.1038/sj.leu.2401573 AndreeffM JiangS ZhangX KonoplevaM EstrovZ SnellVE Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid Leukemia 1999 13 1881 92 10.1038/sj.leu.2401573 Open DOISearch in Google Scholar

37. Zhou JD, Zhang TJ, Xu ZJ, Gu Y, Ma JC, Li XX, et al. BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia. Diagn Pathol 2019, 14: 68. doi: 10.1186/s13000-019-0841-1 ZhouJD ZhangTJ XuZJ GuY MaJC LiXX BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia Diagn Pathol 2019 14 68 10.1186/s13000-019-0841-1 Open DOISearch in Google Scholar

38. Bilbao-Sieyro C, Rodríguez-Medina C, Florido Y, Stuckey R, Sáez MN, Sánchez-Sosa S, et al. BCL2 expression at post-induction and complete remission impact outcome in acute myeloid leukemia. Diagnostics 2020, 10: 1048. doi: 10.3390/diagnostics10121048 Bilbao-SieyroC Rodríguez-MedinaC FloridoY StuckeyR SáezMN Sánchez-SosaS BCL2 expression at post-induction and complete remission impact outcome in acute myeloid leukemia Diagnostics 2020 10 1048 10.3390/diagnostics10121048 Open DOISearch in Google Scholar

39. Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic subclones confer resistance to venetoclax-based therapy in acute myeloid leukemia patients. Cancer Discov 2020, 10: 536–51. doi: 10.1158/2159-8290.CD-19-0710 PeiS PollyeaDA GustafsonA StevensBM MinhajuddinM FuR Monocytic subclones confer resistance to venetoclax-based therapy in acute myeloid leukemia patients Cancer Discov 2020 10 536 51 10.1158/2159-8290.CD-19-0710 Open DOISearch in Google Scholar

40. Kuusanmäki H, Leppä AM, Pölönen P, Kontro M, Dufva O, Deb D, et al. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica 2020, 105: 708–20. doi: 10.3324/haematol.2018.214882 KuusanmäkiH LeppäAM PölönenP KontroM DufvaO DebD Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia Haematologica 2020 105 708 20 10.3324/haematol.2018.214882 Open DOISearch in Google Scholar

41. Del Poeta G, Ammatuna E, Lavorgna S, Capelli G, Zaza S, Luciano F, et al. The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia. Br J Haematol 2010, 149: 383–7. doi: 10.1111/j.1365-2141.2010.08098.x Del PoetaG AmmatunaE LavorgnaS CapelliG ZazaS LucianoF The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia Br J Haematol 2010 149 383 7 10.1111/j.1365-2141.2010.08098.x Open DOISearch in Google Scholar

42. Sharawat SK, Bakhshi R, Vishnubhatla S, Gupta R, Bakhshi S. BAX/BCL2 RMFI ratio predicts better induction response in pediatric patients with acute myeloid leukemia. Pediatr Blood Cancer 2013, 60: E63–6. doi: 10.1002/pbc.24518 SharawatSK BakhshiR VishnubhatlaS GuptaR BakhshiS BAX/BCL2 RMFI ratio predicts better induction response in pediatric patients with acute myeloid leukemia Pediatr Blood Cancer 2013 60 E63 6 10.1002/pbc.24518 Open DOISearch in Google Scholar

43. Huls M, Russel FG, Masereeuw R. The role of ATP binding cassette transporters in tissue defense and organ regeneration. J Pharmacol Exp Ther 2009, 328: 3–9. doi: 10.1124/jpet.107.132225 HulsM RusselFG MasereeuwR The role of ATP binding cassette transporters in tissue defense and organ regeneration J Pharmacol Exp Ther 2009 328 3 9 10.1124/jpet.107.132225 Open DOISearch in Google Scholar

44. Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T; SHG AML96 Study Group. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 2005, 128: 324–32. doi: 10.1111/j.1365-2141.2004.05319.x SchaichM SoucekS ThiedeC EhningerG IllmerT SHG AML96 Study Group MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia Br J Haematol 2005 128 324 32 10.1111/j.1365-2141.2004.05319.x Open DOISearch in Google Scholar

45. van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, Knauf WU, Fey MF, Verhoef GE, et al. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol 2007, 86: 329–37. doi: 10.1007/s00277-007-0269-7 van den Heuvel-EibrinkMM van der HoltB BurnettAK KnaufWU FeyMF VerhoefGE CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age Ann Hematol 2007 86 329 37 10.1007/s00277-007-0269-7 Open DOISearch in Google Scholar

46. Shman TV, Fedasenka UU, Savitski VP, Aleinikova OV. CD34⁺ leukemic subpopulation predominantly displays lower spontaneous apoptosis and has higher expression levels of Bcl-2 and MDR1 genes than CD34-cells in childhood AML. Ann Hematol 2008, 87: 353–60. doi: 10.1007/s00277-008-0439-2 ShmanTV FedasenkaUU SavitskiVP AleinikovaOV CD34⁺ leukemic subpopulation predominantly displays lower spontaneous apoptosis and has higher expression levels of Bcl-2 and MDR1 genes than CD34-cells in childhood AML Ann Hematol 2008 87 353 60 10.1007/s00277-008-0439-2 Open DOISearch in Google Scholar

47. Varatharajan S, Abraham A, Karathedath S, Ganesan S, Lakshmi KM, Arthur N, et al. ATP-binding cassette transporter expression in acute myeloid leukemia: association with in vitro cytotoxicity and prognostic markers. Pharmacogenomics 2017, 18: 235–44. doi: 10.2217/pgs-2016-0150 VaratharajanS AbrahamA KarathedathS GanesanS LakshmiKM ArthurN ATP-binding cassette transporter expression in acute myeloid leukemia: association with in vitro cytotoxicity and prognostic markers Pharmacogenomics 2017 18 235 44 10.2217/pgs-2016-0150 Open DOISearch in Google Scholar

48. Hirsch P, Tang R, Marzac C, Perrot JY, Fava F, Bernard C, et al. Prognostic impact of high ABC transporter activity in 111 adult acute myeloid leukemia patients with normal cytogenetics when compared to FLT3, NPM1, CEBPA and BAALC. Haematologica 2012, 97: 241–5. doi: 10.3324/haematol.2010.034447 HirschP TangR MarzacC PerrotJY FavaF BernardC Prognostic impact of high ABC transporter activity in 111 adult acute myeloid leukemia patients with normal cytogenetics when compared to FLT3, NPM1, CEBPA and BAALC Haematologica 2012 97 241 5 10.3324/haematol.2010.034447 Open DOISearch in Google Scholar

49. Marzac C, Teyssandier I, Calendini O, Perrot JY, Faussat AM, Tang R, et al. Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia. Clin Cancer Res 2006, 12: 7018–24. doi: 10.1158/1078-0432.CCR-06-0641 MarzacC TeyssandierI CalendiniO PerrotJY FaussatAM TangR Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia Clin Cancer Res 2006 12 7018 24 10.1158/1078-0432.CCR-06-0641 Open DOISearch in Google Scholar

50. Smeets ME, Raymakers RA, Vierwinden G, Pennings AH, Wessels H, de Witte T. Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by down-regulating multidrug resistance. Blood 1999, 94: 2414–23. doi: 10.1182/blood.V94.7.2414.417k01_2414_2423 SmeetsME RaymakersRA VierwindenG PenningsAH WesselsH de WitteT Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by down-regulating multidrug resistance Blood 1999 94 2414 23 10.1182/blood.V94.7.2414.417k01_2414_2423 Open DOISearch in Google Scholar

51. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997 89: 3323–9. doi: 10.1182/blood.V89.9.3323 LeithCP KopeckyKJ GodwinJ McConnellT SlovakML ChenIM Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study Blood 1997 89 3323 9 10.1182/blood.V89.9.3323 Open DOISearch in Google Scholar

52. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999, 94: 1086–99. doi: 10.1182/blood.V94.3.1086.415k32_1086_1099 LeithCP KopeckyKJ ChenIM EijdemsL SlovakML McConnellTS Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study Blood 1999 94 1086 99 10.1182/blood.V94.3.1086.415k32_1086_1099 Open DOISearch in Google Scholar

53. Steinbach D, Furchtbar S, Sell W, Lengemann J, Hermann J, Zintl F, et al. Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AML. Leukemia 2003, 17: 470–1. doi: 10.1038/sj.leu.2402806 SteinbachD FurchtbarS SellW LengemannJ HermannJ ZintlF Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AML Leukemia 2003 17 470 1 10.1038/sj.leu.2402806 Open DOISearch in Google Scholar

54. Marzac C, Garrido E, Tang R, Fava F, Hirsch P, De Benedictis C, et al. ATP binding cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients. Haematologica 2011, 96: 1293–301. doi: 10.3324/haematol.2010.031823 MarzacC GarridoE TangR FavaF HirschP De BenedictisC ATP binding cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients Haematologica 2011 96 1293 301 10.3324/haematol.2010.031823 Open DOISearch in Google Scholar

55. Bartholomae S, Gruhn B, Debatin KM, Zimmermann M, Creutzig U, Reinhardt D, et al. Coexpression of multiple ABC-transporters is strongly associated with treatment response in childhood acute myeloid leukemia. Pediatr Blood Cancer 2016, 63: 242–7. doi: 10.1002/pbc.25785 BartholomaeS GruhnB DebatinKM ZimmermannM CreutzigU ReinhardtD Coexpression of multiple ABC-transporters is strongly associated with treatment response in childhood acute myeloid leukemia Pediatr Blood Cancer 2016 63 242 7 10.1002/pbc.25785 Open DOISearch in Google Scholar

56. Galimberti S, Guerrini F, Carulli G, Fazzi R, Palumbo GA, Morabito F, et al. Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis. Eur J Haematol 2004, 72: 45–51. doi: 10.1046/j.0902-4441.2003.00185.x GalimbertiS GuerriniF CarulliG FazziR PalumboGA MorabitoF Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis Eur J Haematol 2004 72 45 51 10.1046/j.0902-4441.2003.00185.x Open DOISearch in Google Scholar

57. Guo X, Shi P, Chen F, Zha J, Liu B, Li R, et al. Low MDR1 and BAALC expression identifies a new subgroup of intermediate cytogenetic risk acute myeloid leukemia with a favorable outcome. Blood Cells Mol Dis 2014, 53: 144–8. doi: 10.1016/j.bcmd.2014.05.001 GuoX ShiP ChenF ZhaJ LiuB LiR Low MDR1 and BAALC expression identifies a new subgroup of intermediate cytogenetic risk acute myeloid leukemia with a favorable outcome Blood Cells Mol Dis 2014 53 144 8 10.1016/j.bcmd.2014.05.001 Open DOISearch in Google Scholar

58. Liu B, Li LJ, Gong X, Zhang W, Zhang H, Zhao L. Co-expression of ATP binding cassette transporters is associated with poor prognosis in acute myeloid leukemia. Oncol Lett 2018, 15: 6671–7. doi: 10.3892/ol.2018.8095 LiuB LiLJ GongX ZhangW ZhangH ZhaoL Co-expression of ATP binding cassette transporters is associated with poor prognosis in acute myeloid leukemia Oncol Lett 2018 15 6671 7 10.3892/ol.2018.8095 Open DOISearch in Google Scholar